QLG1080
/ Qilu Pharma
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
February 20, 2025
Efficacy and Safety Study of QLG1080 in Patients With Hormone-sensitive Advanced Prostate Cancer
(clinicaltrials.gov)
- P3 | N=110 | Not yet recruiting | Sponsor: Qilu Pharmaceutical Co., Ltd.
New P3 trial • Genito-urinary Cancer • Oncology • Prostate Cancer • Solid Tumor
1 to 1
Of
1
Go to page
1